Athan Kuliopulos
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$11.0MFederal grants as PI18 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
18 awards · $11.0M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Dec 6, 2024 | NIH | STTR Phase II Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy | $50K | OASIS PHARMACEUTICALS, LLC |
| Jan 23, 2024 | NIH | STTR Phase II Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy | $1000K | OASIS PHARMACEUTICALS, LLC |
| Jan 18, 2023 | NIH | STTR Phase II Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy | $1000K | OASIS PHARMACEUTICALS, LLC |
| Aug 19, 2022 | NIH | STTR Phase I Development of liver homing PAR2 pepducins for the treatment of Hepatocellular Carcinoma | $392K | OASIS PHARMACEUTICALS, LLC |
| Aug 31, 2021 | NIH | STTR Phase I Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy | $362K | OASIS PHARMACEUTICALS, LLC |
| Apr 2, 2020 | NIH | STTR Phase II PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis | $741K | OASIS PHARMACEUTICALS, LLC |
| Aug 29, 2019 | NIH | SBIR Phase II Development of PAR2 Pepducins as a Novel NASH Treatment | $1.1M | OASIS PHARMACEUTICALS, LLC |
| Apr 3, 2019 | NIH | STTR Phase II PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis | $751K | OASIS PHARMACEUTICALS, LLC |
| Aug 28, 2018 | NIH | SBIR Phase II Development of PAR2 Pepducins as a Novel NASH Treatment | $1.1M | OASIS PHARMACEUTICALS, LLC |
| May 18, 2018 | NIH | STTR Phase II PAR2 Pepducins as a Novel Treatment of Idiopathic Pulmonary Fibrosis | $226K | OASIS PHARMACEUTICALS, LLC |
| Sep 14, 2017 | NIH | SBIR Phase II Development of PAR2 Pepducins as a Novel NASH Treatment | $1.0M | OASIS PHARMACEUTICALS, LLC |
| Aug 18, 2017 | NIH | STTR Phase II Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis | $750K | OASIS PHARMACEUTICALS, LLC |
| May 1, 2017 | NIH | STTR Phase I Development of PAR Pepducins as a Novel Antithrombotic Treatment | $366K | OASIS PHARMACEUTICALS, LLC with TUFTS MEDICAL CENTER |
| Apr 30, 2017 | NIH | STTR Phase I Development of PAR4 Pepducins as a Novel Antithrombotic Treatment | $366K | OASIS PHARMACEUTICALS, LLC |
| Aug 22, 2016 | NIH | STTR Phase II Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis | $750K | OASIS PHARMACEUTICALS, LLC |
| Aug 26, 2015 | NIH | STTR Phase II Development of PAR2 Pepducins for the Treatment of Atopic Dermatitis | $225K | OASIS PHARMACEUTICALS, LLC |
| Jun 5, 2015 | NIH | STTR Phase II Supplement to grant 5R42DK101240 Oasis Pharmaceuticals to attend BIO conference | $5K | OASIS PHARMACEUTICALS, LLC |
| Mar 31, 2015 | NIH | STTR Phase II Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis | $871K | OASIS PHARMACEUTICALS, LLC |
Peer ranks
Federal funding#53
Awards as PI#24
Patents#273
Companies
- OASIS PHARMACEUTICALS, LLCLinked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.